Clin2
NCT04123314Possibly a fitRecruiting

Psilocybin study for depression in mild memory or early Alzheimer’s

Depressive SymptomsDepressionAlzheimer DiseaseMild Cognitive Impairment

Treatments studied

Part of Brain & nervous system, Mental health clinical trials.

This early-phase study tests whether psilocybin (a psychedelic substance) can help with depression in people who have mild memory problems or early Alzheimer’s. The trial also closely monitors safety, thinking changes, mood, and blood pressure before and after dosing.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
20 people
Ages
18 years to 85 years
Study type
Interventional

Who can take part

  • You have mild cognitive impairment or early Alzheimer’s—either by clinical diagnosis or by memory test results (including CDR Memory > 0.5).
  • Your thinking test scores must be within range (Mini-Mental State Exam over 18, and Montreal Cognitive Assessment under 26).
  • You have depression symptoms at least mildly to moderately (based on a depression rating like CSDD or GDS-Short Form).
  • You must have a close friend or family member who can act as an informant/community observer during study visits.
  • You must be able to take part safely with your current medicines and have stable antidepressant regimens (SSRI/SNRI and/or bupropion) for the required time.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06512194Recruiting· Phase 2
Psilocybin for depression study

This trial tests whether psilocybin can help people with major depression who are currently having a depressive episode. It aims to understand how the treatment works and if it is safe and effective.

Edwards, Colorado
NCT07582120Not yet recruiting· Phase 2
Psilocybin-Assisted Therapy for Depression

This study tests whether psilocybin (a naturally occurring psychedelic compound) combined with therapy can help treat depression. Researchers will give you a single dose of psilocybin in a controlled medical setting while providing psychological support to see if it reduces your depression symptoms.

St Louis, Missouri
NCT06656702Recruiting· Early Phase 1
Psilocybin for depression in amyotrophic lateral sclerosis

This trial tests whether psilocybin, a psychedelic drug, can safely help with depression in people with ALS. It also looks at how the drug affects your symptoms and quality of life over six months.

Baltimore, Maryland
NCT07721467Not yet recruiting· Phase 2
Can psilocybin and brain training help memory?

This study tests whether combining psilocybin (a psychedelic drug) with mental exercises can improve memory and thinking in older adults, both those with early Alzheimer's and those without memory problems. It aims to see if this combination can boost brain flexibility.

Baltimore, Maryland
NCT06072898Recruiting· Phase 2
Psilocybin brain imaging trial for depression

This study tests whether a single dose of psilocybin (a psychedelic compound) can help treat depression by looking at brain changes on MRI. It is designed for people with moderate-to-severe depression who have not responded well to other treatments.

Toronto, Ontario
NCT06442423Recruiting· Phase 1
Psilocybin study for people with psychiatric symptoms

This trial tests if psilocybin, a substance found in certain mushrooms, can help people with various mental health symptoms that affect daily life. You would take a single dose in a supervised setting and be monitored for changes in your mood and well-being.

New Haven, Connecticut

Hear when a new Depressive Symptoms trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.